Most recently, Parsey worked at Genentech, a member of the Roche Group as the senior group medical director in Genentech Research and Early Development, overseeing early clinical development in multiple therapeutic areas.
3-V Biosciences executive chairman, who is returning to his role as chairman of the board David Mott said that Merdad’s extensive drug development experiences in different therapeutic areas, including infectious disease, coupled with his experience in respiratory medicine, make him an excellent choice to lead the team.
Parsey said that he is excited to join the 3-V team and help turn this exciting science into therapies that have the potential to improve the lives of patients.